%0 Journal Article
%T Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study
%A Anne B£¿rjesson-Hanson
%A Brendon Binneman
%A Carol L. Cronenberger
%A Catherine A. Sattler
%A Henrik £¿stlund
%A Martin M. Bednar
%A Niels Andreasen
%A Pamela F. Schwartz
%J Archive of "Alzheimer's & Dementia : Translational Research & Clinical Interventions".
%D 2017
%R 10.1016/j.trci.2017.05.003
%X The safety, pharmacokinetics, and effect on peripheral and central amyloid ¦Â (A¦Â) of multiple doses of ponezumab, an anti-A¦Â monoclonal antibody, were characterized in subjects with mild-to-moderate Alzheimer's disease treated for 1 year
%K Alzheimer's disease
%K Antibody
%K Amyloid
%K Pharmacokinetics
%K Pharmacodynamics
%K Ponezumab
%K PIB
%K Safety
%K Tolerability
%K Anti-drug antibodies
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651442/